MedMira Grows Rapid HIV Test Sales in Latin America

Receives Product Registration and Initial Order for Argentina

Apr 20, 2006, 01:00 ET from MedMira Inc.

    HALIFAX, April 20 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira")
 (TSX Venture: MIR, NASDAQ:   MMIRF) the global market leader in premium rapid
 diagnostic solutions, announced today that it has received an initial order
 for MiraWell(R) Rapid HIV Tests (MiraWell HIV) from its agent, EXPORTRADE
 CORP (EXPORTRADE) of Boca Raton, Florida. The tests will be sold to
 hospitals, physicians and various government testing programs in Argentina
 through AC Corp., a member of EXPORTRADE's distribution network. Prior to
 receiving this order, MedMira and EXPORTRADE worked together to secure
 official product registration for MiraWell HIV in Argentina, an important
 first step in opening the market for sale of MedMira products.
     "We consider product registration and subsequent sales activity in
 Argentina to be a critical step in developing the Latin American market,"
 said Giles Crouch, vice president of global sales & marketing, MedMira.
 "Working closely with EXPORTRADE in Argentina, as well as with our other
 representatives in Latin America to achieve country registrations followed
 by sales, will allow us to continue growing this market for our rapid HIV
 tests and future products, including co-infection tests for HIV and
 Hepatitis C."
     Most rapid HIV testing is conducted in professional labs in Argentina
 using serum/plasma. The MiraWell HIV test can be used with serum/plasma as
 well as whole blood, which will open further markets in rural areas where
 no suitable lab facilities are readily available.
     Crouch continued, "Product and technical training with EXPORTRADE's
 in-country representatives will begin shortly and we look forward to
 launching MiraWell HIV nationally within the next few months."
     Rapid HIV tests are a key tool in preventing and controlling the spread
 of HIV. Some 1.8 million Latin Americans are infected with the HIV-AIDS
 virus, according to the United Nations, with Brazil, Argentina and Colombia
 the worst hit. Providing instant test results will help increase the number
 of people who know their HIV status and subsequently seek appropriate
 medications and treatment.
     About MedMira
     MedMira is the leading global manufacturer and marketer of in vitro
 flow-through rapid diagnostic tests. MedMira's tests provide reliable,
 rapid diagnosis in just 3 minutes for the detection of human antibodies in
 human serum, plasma or whole blood for diseases such as HIV and hepatitis
 C. The United States FDA and the SFDA in the People's Republic of China
 have approved MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests,
     MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently
 used in clinical laboratories, hospitals, and clinics where professional
 counselling and patient treatment are immediately available.
     The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
 (OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
 Regions, in the People's Republic of China. MiraCare(TM) is sold through
 MedMira's distributor network to pharmacies, hospitals and laboratories in
 the European Union.
     MedMira delivers rapid diagnostic solutions to healthcare communities
 around the globe. Its corporate offices and manufacturing facilities are
 located in Halifax, Nova Scotia, Canada with a representative office in
 Guilin, China.
     This news release contains forward-looking statements, which involve
 risk and uncertainties and reflect the company's current expectation
 regarding future events. Actual events could materially differ from those
 projected herein and depend on a number of factors including, but not
 limited to, changing market conditions, successful and timely completion of
 clinical studies, uncertainties related to the regulatory approval process,
 establishment of corporate alliances and other risks detailed from time to
 time in the company quarterly filings.
     The TSX Venture Exchange has not reviewed and does not accept
     responsibility for the adequacy or accuracy of this statement.
     For more information visit MedMira's website at

SOURCE MedMira Inc.